N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide

Independent reference data for N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide (CAS 391209-97-5), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Physicochemical values on record

Documented uses on record

Mirdametinib is indicated for the treatment of neurofibromatosis type 1 (NF1) in patients two years and older with symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection.Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; MEK inhibitors

Synonyms and trade names

391210-10-9; Mirdametinib; PD0325901; PD 0325901; PD-0325901; N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide; GOMEKLI; PD 325901; 86K0J5AK6M; DTXSID0044024; DTXCID8024024; CHEBI:88249; Pd 901; PD-901; Benzamide, N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-; PD-03525901

GHS hazard classification

Reported hazard statements	H301 (97.5%), H373 (97.5%), H400 (95%), H410 (97.5%)

H301 (97.5%): Toxic if swallowed [Danger Acute toxicity, oral]

H373 (97.5%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]

What the public record says

N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide · CAS 391209-97-5 · C16H14F3IN2O4. UNII 86K0J5AK6M. Dissociation Constants: 7.96.

Physical description and handling notes

Source: PubChem / Wikidata; the batch COA governs where values differ.